FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
It is intended for the treatment of adult patients with urothelial cancer
Findings from a large, prospective cohort study of patients with inflammatory bowel disease diagnosed in Norway and Sweden
Findings from the first population-based study to examine SARS-CoV-2 infections in survivors of childhood, adolescent, and young adult cancer compared with matched population controls
Efficacy was evaluated in CHECKMATE-816 study
Classifications is proposed according sensitivity of atypical EGFR mutations to tyrosine kinase inhibitors
New indication concerns the use in patients with early breast cancer at high risk of recurrence
Promising clinical benefit associated with an enrichment of bacterial species, circulating cytokines and immune cell populations in responders
SOLO2 ancillary study findings will help assure patients that their outcomes will not be adversely affected when dose reductions or interruptions are needed
New indications concern the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma and the adjuvant treatment of muscle invasive urothelial carcinoma
Most patients were on active anticancer treatment during the 28 days before the administration of third dose
Findings from the international metastatic renal cell database consortium
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.